^
    Back
    Association details:
    Biomarker:ER D538G
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:Fablyn (lasofoxifene) (Selective estrogen receptor modulator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Breast Cancer Res
    Title:

    Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer

    Published date:
    05/12/2021
    Excerpt:
    …MCF7 cells bearing wild-type, Y537S, or D538G ERα were injected into the mammary ducts of NSG mice (MIND model)…The results demonstrate the potential of using lasofoxifene as an effective therapy for women with advanced or metastatic ER+ breast cancers expressing the most common constitutively active ERα mutations.
    DOI:
    10.1186/s13058-021-01431-w
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO 2018
    Title:

    Lasofoxifene efficacy in a mammary intraductal (MIND) xenograft model of ERa+ breast cancer

    Published date:
    05/16/2018
    Excerpt:
    ...tumor growth as measured by tumor weight, of MCF7 WT and MCF7 D538G explants was significantly inhibited versus vehicle by 10 mg/kg lasofoxifene.